FDA warns Israel-based website mysteroidsmarket.com for selling unapproved and misbranded stimulants and benzodiazepines to U.S. consumers.
What happened
FDA reviewed the website www.mysteroidsmarket.com and found it offered Schedule II stimulants and benzodiazepines for sale to U.S. consumers, including products marketed as Adderall XR, clonazepam and Ativan. FDA said no approved applications were in effect for these products and that prescription drugs were offered without a prescription.
What FDA found
The website offered amphetamine products marketed as “Buy Adderall Xr 30mg” and “ADDERALL XR®” without an FDA-approved application.
section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]The website offered clonazepam and lorazepam products without FDA-approved applications.
section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]The website sold prescription drugs without requiring a prescription, so the drugs were misbranded.
section 503(b)(1) and section 301(k) of the FD&C Act [21 U.S.C. §§ 353(b)(1), 331(k)]The labeling for these prescription drugs did not bear adequate directions for use by a layperson.
section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]By offering these drugs to U.S. consumers, the website caused misbranded drugs to be introduced into interstate commerce.
section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]The drugs are unapproved new drugs because they are not generally recognized as safe and effective for their labeled uses.
section 201(p) and section 505(a) of the FD&C Act [21 U.S.C. §§ 321(p), 355(a)]
What FDA wants
FDA asks the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to notify FDA in writing within 15 working days of steps taken to correct the violations and prevent recurrence.
Who should pay attention
- online pharmacies and websites selling to U.S. consumers
- consumers who buy prescription drugs online
- companies that handle or advertise controlled substances
This is a summary. Read the original letter on fda.gov.